Background/Aims: Diabetic dyslipidemia is typically characterized by an increase in plasma triglycerides (TG), a concomitant increase in small dense (sd) low density lipoprotein (LDL) and atherogenic LDL-TG. Angiopoietin like protein 4 (ANGPTL4) is well established regulators of plasma TG level through regulating the activity of lipoprotein lipase. Plasma level and association between ANGPTL4 and sdLDL or LDL-TG is not well established in human subjects. We aimed to examine the level of ANGPTL4 and investigate the association between ANGPTL4 with sdLDL-C and LDL-TG in type 2 diabetes (T2D).

Methods: 250 (M176/F 74) Japanese diabetic patients and 9 of healthy controls (Controls) were enrolled in this study. SdLDL-C and LDL-TG were measured by homogeneous assays. ANGPTL3 and ANGPTL4 protein levels were measured by ELISA.

Results: As compared with Controls, plasma ANGPTL3, ANGPTL4, sdLDL-C and LDL-TG levels were increased in T2D. ANGPTL3 was not collated with sdLDL-C or LDL-TG. ANGPTL4 was positively correlated with HbA1c(r=0.15, p=0.019), TG(r=0.15, p=0.018)and LDL-TG(r=0.17,p=0.008), whereas ANGPTL4 was not collated with sdLDL-C. Furthermore, ANGPTL4 was also significantly associated with LDL-TG/LDL-C ratio (r=0.15, p=0.022) and LDL-TG/apoB ratio (r=0.18, p=0.009).

Conclusions: The ANGPTL4 level was increased in T2D and associated with atherogenic higher LDL-TG levels. ANGPTL4 may play a role in modulating lipid metabolism in LDL particles.


H. Nagaike: None. T. Hayashi: None. N. Nakanishi: None. M. Ohara: None. T. Yamamoto: None. T. Fukui: None. T. Hirano: Speaker's Bureau; Self; Novo Nordisk Inc., AstraZeneca.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at